Filing Flows › Yarrow Bioscience (YARW) › Q4 2024
Yarrow Bioscience (YARW) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 6, 2025
Yarrow Bioscience (YARW) reported revenue of $84K for the fourth quarter 2024 (Q4 2024), +11% from a year earlier and -31% from the quarter before.
Yarrow Bioscience, Q4 2024: revenue $84K (+10% year over year), net loss $12.0M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $84K | -31% | +11% |
| Operating profit | −$12.8M | — | — |
| Net earnings | −$12.0M | — | — |
| Operating cash flow | −$9.0M | — | — |
What changed
Revenue was $84K in Q4 2024, up 11% year over year and down 31% from the previous quarter.
Operating costs exceeded revenue by $12.8M, an operating margin of -15202.4%. Total costs grew 86% against revenue growth of 11%. The fastest-growing cost line was Research & development (+220%). The quarter ended with a net loss of $12.0M, narrower than the previous quarter's $12.2M loss.
Operating cash flow was −$9.0M. Non-cash charges added back $699K of share-based compensation. Working capital and other items added $2.3M.
Questions
What was Yarrow Bioscience's revenue in the fourth quarter 2024?
Yarrow Bioscience (YARW) reported revenue of $84K for the fourth quarter 2024 (Q4 2024), +11% from a year earlier and -31% from the quarter before.
Source: Yarrow Bioscience 10-K on SEC EDGAR.